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Purpose: Variants in IQSEC2, escaping X inactivation, cause X-
linked intellectual disability with frequent epilepsy in males and
females. We aimed to investigate sex-specific differences.
Methods: We collected the data of 37 unpublished patients (18
males and 19 females) with IQSEC2 pathogenic variants and 5
individuals with variants of unknown significance and reviewed
published variants. We compared variant types and phenotypes in
males and females and performed an analysis of IQSEC2 isoforms.
Results: IQSEC2 pathogenic variants mainly led to premature
truncation and were scattered throughout the longest brain-specific
isoform, encoding the synaptic IQSEC2/BRAG1 protein. Variants
occurred de novo in females but were either de novo (2/3) or
inherited (1/3) in males, with missense variants being predomi-
nantly inherited. Developmental delay and intellectual disability
were overall more severe in males than in females. Likewise,
seizures were more frequently observed and intractable, and started
earlier in males than in females. No correlation was observed
between the age at seizure onset and severity of intellectual
disability or resistance to antiepileptic treatments.
Conclusion: This study provides a comprehensive overview of
IQSEC2-related encephalopathy in males and females, and suggests
that an accurate dosage of IQSEC2 at the synapse is crucial during
normal brain development.
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INTRODUCTION
Pathogenic variants on chromosome X represent an important
cause of neurodevelopmental disorders, where expression
usually depends on the sex of the individual.1 X-linked
conditions are often restricted to males, or more severe in
males than in females, because males have a single copy of the
X chromosome while females have two copies.2 EFNB1-related
craniofrontonasal syndrome and PCDH19-related female-
limited epilepsy, two X-linked disorders where heterozygous
females are affected and hemizygous males are spared,
constitute the only exceptions to this rule known so far.3,4
Yet, increasing evidence shows that variants on chromosome
X also account for a significant proportion of affected females
and that some X-linked disorders affect males and females
almost equally. Compensation of gene dosage in females
is achieved for most genes on the X chromosome by epigenetic
silencing of one X chromosome. This process, known as X
chromosome inactivation (XCI), usually occurs randomly
from one cell to another at an early stage of embryonic
development. XCI is stably inherited over subsequent cell
divisions, which ultimately results in somatic mosaicism at the
organism level where statistically half of the cells inactivate the
paternal-derived X chromosome whereas the other half
inactivate the maternal copy.2,5 In females carrying a
pathogenic X-linked variant, skewing of XCI favoring the
expression of the normal allele protects from the disorder
while skewing favoring the expression of the mutated allele has
the opposite effect.6 Consequently, females with X-linked
neurodevelopmental disorders usually have more variable
phenotypes assumed to be related to XCI patterns in the brain.
Interestingly, 15–20% of genes escape XCI and are expressed
from both X alleles in females.7,8 Escapee genes differ from one
mammalian species to the other and both their function and
link with human disorders are still largely unknown.9,10
The IQSEC2 gene on chromosome Xp11.22 encodes a
guanine nucleotide exchange factor (GEF) able to activate
small GTPases of the ARF family, including ARF611,12.
Enriched at the postsynaptic density of excitatory synapses
where it interacts with proteins of the PSD-95 complexes
including PSD-95 itself,12–15 the IQSEC2 (IQ motif and SEC7
domain-containing protein 2) protein acts on shaping
dendritic spine morphology16 and controls excitatory synaptic
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transmission by regulating glutamate (N-methyl-D-aspartate
[NMDA] and α-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid [AMPA]) receptor-mediated responses.17–19
IQSEC2 missense variants were first identified in four large
families, in which almost exclusively males were affected by
nonsyndromic intellectual disability (ID).11 Although a de
novo translocation interrupting IQSEC2 had been described
earlier in a female patient,20 the recognition that IQSEC2
encephalopathy also affects females came from the further
identification of de novo IQSEC2 variants in females with
epileptic encephalopathy or ID.1,21–29 Recently, two families
with affected males and females,18,30 and one family with
affected females only, probably as the result of paternal
gonadal mosaicism,31 were also described.
Remarkably, IQSEC2 is one of the few genes that escape
XCI in humans.7 This property is specific to the human or
primate lineage because Iqsec2, although located in the
homologous region of chromosome X, is conversely subject
to XCI in mice.32 Moreover, IQSEC2 leads to the expression of
at least three different isoforms. The nature of the isoforms
that are relevant for the human disorder and the mechanisms
by which the variants lead to a disorder in males and females
remain mysterious.
In this study, we compared the variant types and clinical
phenotypes of males and females with IQSEC2 pathogenic
variants to gain insights into the mechanisms controlling
phenotypic variability. To this end, we collected unreported
patients with likely pathogenic variants from different clinical
centers and reviewed patients published in the literature.
MATERIALS AND METHODS
Human subjects
We collected clinical and molecular data of 47 patients with
IQSEC2 variants from different clinical centers in France,
Belgium, the Netherlands, Denmark, Czech Republic, Canada,
and the United States through clinical and genetics networks
(Defiscience, AnDDIrare, EuroEPINOMICS consortium). Var-
iants of five patients (patients 10, 12, 22, 30, and 37) were
previously reported without clinical data.28,33 Other patients were
novel. Details on the methods used to detect the IQSEC2 variants
are indicated for each patient in Table S1. The American
College of Medical Genetics and Genomics (ACMG) criteria
and the Intervar interface (http://wintervar.wglab.org/) were
used to filter and classify IQSEC2 variants.34,35 Each referring
physician filled out a table with detailed developmental,
neurological, behavioral, and epileptic medical history,
including electroencephalogram (EEG) and imaging data
where available. Patients were evaluated according to devel-
opmental scales routinely used in enrolled centers
(Brunet–Lezine, HAWIK-IV, SON-R2). Informed written
consent was locally obtained for all participants. The study
was approved by INSERM (RBM C12-06).
Review of published IQSEC2 variants
The terms “IQSEC2” and “variants” or “mutations” were used
to search for articles reporting IQSEC2 patients in PubMed. In
addition, variants present in the Human Gene Mutation
Database (HGMD) professional database (Biobase, Qiagen)
were reviewed. We contacted the authors of the article when
information on sex of the patient and inheritance/status of the
variant was unavailable or to rule out the possibility that
patients with identical variants are duplicates. The accuracy of
variant description was checked using Alamut 2.10 (Inter-
active Biosoftware). Deletions encompassing IQSEC2 and
additional genes were excluded from the review. IQSEC2
variants are indicated on the longest isoform (complementary
DNA: NM_001111125.2/ENST00000396435.8; protein:
NP_001104595.1) unless specified differently, according to
Human Genome Variation Society (HGVS) guidelines (www.
hgvs.org/mutnomen). Pathogenic variants and corresponding
patient data (sex, status, variant inheritance) were listed
(Table S2) and visualized on the schematic representation of
IQSEC2 (Fig. 1b).
IQSEC2 isoforms
A manual review of the existing GENCODE (ENST) and
RefSeq (NM) annotation of the IQSEC2 locus (GRCh38) was
performed collaboratively by an LRG project curator and a
GENCODE annotator and found to be satisfactory (pending
LRG_1194). The shortest isoform (ENST00000639161.1/
NM_001243197.1) was not yet annotated in the GRCh37/
hg19 genome annotation used by most publicly available
transcript quantification projects (e.g., GTex), so isoform
expression was determined using alternative methods.
Promoter usage was determined using Fantom5 Cap Analysis
Gene Expression (CAGE) data from the Riken consortium,
accessed using the SSTAR portal (TSS expression).36 Isoform
specific expression was determined by quantifying intron-
spanning reads of isoform specific exon–exon boundaries in
publicly available RNA-seq data sets (accessed through ENA).
Exon–exon boundaries quantified were (GRCh38 coordi-
nates): NM_001111125.2/ENST00000396435.8, introns 1
(chrX:53291925:53320416) and 2 (chrX:53256062:53291894);
NM_015075.1/ENST00000375365.2, intron 2 (chrX:532560
62:53279563); NM_001243197.1/ENST00000639161.1, intron
2 (chrX_53267065:53279563). Additional information is
provided in Table S3.
Genotype–phenotype correlations
Means and frequencies were compared using the Fisher’s
exact test or Wilcoxon–Mann–Whitney test where appro-
priate. Comparative violin plots were drawn using Seaborn, a
Python visualization library based on Matplotlib (https://
seaborn.pydata.org/index.html).
RESULTS
We collected the data from 37 unpublished patients (18 males
and 19 females) with IQSEC2 pathogenic variants, 5
individuals (4 males and 1 female) with variants previously
reported without clinical data, and 5 novel patients (3 males
and 2 females) with variants of unclear significance (VUS)
from 45 unrelated families (Table 1): one splice-site variant
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inherited from an asymptomatic mother was present in two
brothers (patients 5 and 6) and a missense VUS was present
in a male and his maternal uncle (patients 45 and 46;
Table S1, Fig. 1). We also reviewed information from 100
carrier individuals from 52 published families (Table S2). The
sex ratio for affected individuals from the literature was 54
males to 23 females (sex unknown for 9 affected individuals).
A total of 15 unaffected heterozygous female carriers from 4
families were also described.11
IQSEC2 isoforms
The longest IQSEC2 isoform (NM_001111125.2/
NP_001104595.1) comprises 15 exons and encodes a 1488
amino acid (aa) protein (Fig. 1a, b). The corresponding
protein is part of the PSD-95 multiprotein complexes in
glutamatergic synapses.14,15 It contains an N-terminal coiled
coil (CC) domain, an IQ calmodulin-binding motif, SEC7 and
Pleckstrin homology (PH) domains, as well as a 4-aa PDZ-
binding motif (STVV) located at the C-terminus and required
for interaction with synaptic PDZ proteins (PSD-95, SAP102,
MAGI1, MAGI2).13 This protein has also been described in
the literature as BRAG1 (brefeldin A resistant Arf-guanine
nucleotide exchange factor 1).
Our analysis of large-scale expression data sets (GTex,
Fantom) confirms that the use of the upstream promoter (P2),
which gives rise only to the longest isoform
(NM_001111125.2/NP_001104595.1), is the dominant form
expressed across multiple brain tissues (Fig. 2a).
Two additional isoforms arising through the use of an
alternative downstream promoter (P1) and including alter-
native 5′ exons exist (Fig. 1a). The shortest isoform
(NM_001243197.1/NP_001230126.1) does not share any
exons with the longest isoform and encodes an entirely
distinct 73 aa protein containing a poly-E motif with
homology to cobalamin biosynthesis domain. The coding
sequence of this unstudied protein is conserved in mammals,
suggesting that it has an important, although possibly
completely distinct, function and localization (Fig. S1). The
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Fig. 1 Schematic representation of IQSEC2 isoforms and location of pathogenic IQSEC2 variants on the longest isoform. (a) Schematic repre-
sentation of the three IQSEC2 isoforms resulting from alternative promoter usage (P1 vs. P2) and splicing. Blue/gray boxes respectively indicate exons
present/absent in the longest isoform. The pink star indicates the location of the IQSEC2 variant (unknown significance) identified in patient 47. (b) Location
of IQSEC2 pathogenic variants reported in this study (above) or in the literature (below) on the schematic representation of the longest NM_001111125.2
isoform (numbered blue boxes correspond to exons) and corresponding protein domains: N-terminal coiled coil (CC) domain, IQ calmodulin-binding motif
(IQ), SEC7 and Pleckstrin homology (PH) domains, and PDZ-binding motif (STVV). Square: predicted truncating variants; circle: missense variants; triangle: in-
frame deletion; bow tie: splice variants; pink: variants present in affected females; blue: variants present in affected males; yellow: variants present in
affected males and females. Red dot: de novo occurrence; green dot: maternal inheritance; orange dot: suspected gonadal mosaicism. No dot indicates
inheritance is unknown. Horizontal lines indicate the extent of large deletions on the corresponding coding sequence. Variants underlined: previously
published without clinical data and included in this study. Variants of unknown significance (VUS) or variants from the literature for which sex was unknown
are not indicated on this schematic
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third isoform (NM_015075.1/NP_055890.1) is a combination
of 5′ exons from the shortest isoform and 3′ exons from the
longest isoform. This results in a 949 residue protein that also
lacks the PDZ-binding domain, but does contain IQ, Sec7,
and PH domains in common with the longest form (Fig. 1a).
Both of these non-PDZ containing isoforms are broadly
expressed across a range of tissues but at a relatively low level
in the brain (Fig. 2a). Of the two, the previously unstudied,
shortest isoform (NM_001243197.1/NP_001230126.1) is
much more highly expressed in the brain and other tissues
than the intermediate NM_015075.1/NP_055890.1 form
(Fig. 2b).
All pathogenic IQSEC2 variants from our series and the
literature were scattered throughout the exons of the longest
brain-specific NM_001111125.2/NP_001104595.1 isoform
(Fig. 1b), confirming that the disorder is mainly due to the
alteration of the synaptic IQSEC2/BRAG1 protein. Interest-
ingly however, a female individual with developmental delay,
ID, stereotypies, and pharmacoresistant seizures had a
frameshift deletion located in the alternative exon 1
(NM_015075.1:c.12del, NP_055890.1:p.Arg6Glyfs*24, patient
47), therefore altering only the shorter isoforms
(NM_015075.1 and NM_001243197.1, Fig. 1a), which was
also present in her unaffected mother (Table S1). This variant
was considered as a VUS, based on the maternal inheritance
and unusual location restricted to the short isoforms.
IQSEC2 variant spectrum
Overall, most pathogenic variants identified in our patient
series are predicted to lead to premature termination codons
(n= 35/40; including 15 frameshifts; 16 nonsense; 4 splice-
site variants) altering exons of the long isoform
(NM_001111125.2/ NP_001104595.1, Fig. 1b). Only four
novel missense variants, three in the SEC7 domain of IQSEC2
(p.Gly760Ser and p.Gly771Asp in females 21 and 22, and p.
Pro785Leu in male 25) and one in the PH domain
(p.Arg1069Pro in male 33) were classified as likely pathogenic
based on their de novo occurrence and/or their predicted in
silico damage. Additionally, a de novo in-frame deletion,
leading to the loss of 211 amino acids and the insertion
of a glycine in exon 5, was classified as pathogenic
(p.Thr523_Thr733delinsGly in male 24). In addition to the
VUS altering the short isoforms, three missense variants,
located in exons 9 (p.Val918Phe in male 43), 13 (p.
Ala1139Thr in female 44) and 14 (p.Arg1155Trp in a male
and his affected uncle, patients 45 and 46) of the long isoform
were classified as VUS due to unusual or mild phenotypes
and/or insufficient evidence for pathogenicity. The observa-
tion of females with frameshift variants leading to a late C-
terminal truncation of the protein indicates that the four last
amino acids, necessary for the interaction with PDZ proteins,
are required for the function of the protein at the synapse.
Excluding previously published variants and VUS, patho-
genic variants mainly lead to premature truncation in females
(18 truncating, 1 missense) while males had a broader range
of variant types (10 truncating, 4 splice, 3 missense, 1 in-
frame deletion). This tendency was confirmed taking data
from the literature into account where missense variants were
more frequent in males (13 truncating, 2 splice, 11 missense, 1
in-frame deletion) than in females (11 truncating, 1 missense,
1 in-frame deletion; combined p value= 0.003, Fisher’s exact
test).
In our series, all pathogenic variants for which inheritance
could be investigated occurred de novo in females (12/12
individuals). In contrast, males had either de novo (n= 12/16)
or maternally inherited (4/16) pathogenic variants. Including
previously reported individuals, 11/12 variants identified in
females occurred de novo with a gonadal mosaicism suspected
in the remaining family with multiple affected females; in
males, 13 variants occurred de novo while 8 were maternally
inherited. Overall, missense variants were therefore more
frequently inherited (8/14) than de novo (6/14). Conversely,
truncating variants were predominantly de novo (42/44 for
which inheritance could be determined; p= 5.6E-5, Fisher’s
80
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Fig. 2 The PDZ-binding domain IQSEC2 isoform (NM_001111125.2 /
NP_001104595.1) is the dominant form expressed specifically in
brain. Expression of IQSEC2 isoforms across multiple tissues was quantified
using two different methods. (a) Cap Analysis of Gene Expression (CAGE)
data shows that the upstream transcription start site (P2), which gives rise
only to NM_001111125.2/ENST00000396435.8, is strongly and specifically
expressed in the brain while the downstream transcription start site (P1) is
more broadly expressed across other tissues. Tissues were chosen based on
relatively strong expression of any TSS and sample data, then grouped by
tissue. (b) Isoform specific intron-spanning RNA-seq reads were quantified
to show relative levels of isoform expression, again confirming that
NM_001111125.2 is the dominant brain form. Between the two non-PDZ-
binding domain forms (NM_001243197.1/ENST00000639161.1 and
NM_015075.1/ENST00000375365.2) the shortest form NM_001243197.1
is the isoform predominantly expressed in nonneuronal tissues, and it is also
weakly expressed in the brain. Tissues were chosen based on Fig. 2a, but
are more limited due to data availability. All data are mean +/− SEM,
individual sample data are provided in Table S3
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exact test). Variants altering splice sites were either de novo
(n= 2) or inherited (n= 3) in males. Altogether, this indicates
that pathogenic IQSEC2 variants are inherited in 30% of male
patients (12/40) and de novo in the remaining 70%, and that
missense variants are more frequently inherited than truncat-
ing variants, possibly because they are better tolerated in
female carriers than truncating variants.
XCI status was studied from genomic DNA extracted from
blood in six affected female patients and the three asympto-
matic female carriers with heterozygous VUS (Table S1). Four
of five affected females had random XCI patterns while two
showed skewed (100:0 and 80:20) XCI. The mother of the
male patient with p.Val918Phe had a 80:20 XCI pattern while
two female carriers with p.Arg1155Trp respectively had 38:62
and 7.6:92.4 XCI ratios.
Neurodevelopment
The study includes 20 females and 22 males with pathogenic
IQSEC2 variants aged from 1.4 to 43 years (Tables S1 and 2).
Most patients had normal pregnancy, delivery, and neonatal
examination. All patients had developmental delay with ID
ranging from mild to profound. Males had severe to profound
ID while females had mild to severe ID (mild to moderate,
n= 6/17; Fig. 3a). Developmental milestones were delayed in
the first years of life in most patients, and the delay was
significantly more severe in males than in females (mean age
at sitting/walking unsupported: 10.2/24.5 months in females
versus 20.2/30.3 in males; Table 2). Overall, of the 17 patients
older than 3 years who were unable to walk unsupported,
one was a female while all others were males. Data on
language acquisitions, available for 41 patients, also revealed
that male patients had a more severe language delay than
female patients, with 20/22 males versus 4/19 females being
nonverbal (p= 6.2E−6, Fisher’s exact test).
Manner of hand use was known for 38 patients. Females
showed a purposeful use of hands more frequently than males
although hand stereotypies were observed in both groups
(Table 2). Behavioral issues were reported for 29 patients (13
females and 16 males), including autistic behaviors in 20 (8
females and 12 males), self-injurious behaviors in 8 (4 females
and 4 males), temper tantrum, and hyperactivity. The
behavior of 7 patients was considered as nonproblematic.
Other issues were sleep disorders (early awakening, insomnia)
reported in 7 patients and feeding difficulties (poor chewing,
regurgitations) mentioned in 10 patients, requiring
gastrostomy-tube feeding in 3 patients.
Epilepsy
Overall, 35/42 patients had epilepsy, including 14/20 (70%)
females and 21/22 (95%) males (p= 0.04, Fisher’s exact test).
Patients without seizures were mainly females (6/7) with mild
(n= 1) to severe (n= 1) ID. In epileptic patients, first seizures
were noticed at a mean age of 40.6 months. Females had on
average a later age at seizure onset (66.4 months versus
23.9 months in males) although the difference was not
statistically significant (Table 2, Fig. 3b).
Polymorphic seizures were observed in most patients. Two
male patients had no convulsive seizures but EEG showed
continuous or subcontinuous spikes–waves during sleep. The
most frequent seizure types were, by descending order of
frequency: atypical absences (n= 17), generalized tonic–clonic
seizures (n= 13), tonic seizures (n= 12), atonic seizures
(n= 11), myoclonic seizures (n= 10), spasms (n= 9), dys-
cognitive and clonic seizures (n= 4). Atonic seizures, spasms,
and myoclonic seizures occurred more frequently in males
than in females (Table 2). EEG recordings were characterized
by a slowing of the background activity (n= 16/30), with
multifocal (n= 8), focal (n= 6), or generalized (n= 8) spikes
and/or spikes–waves, or with bursts of focal slow waves
(n= 5). Hypsarrhythmia was considered in four patients.
Factors triggering seizures were reported in ten patients,
including fever (n= 5), sleep (n= 4), contact with water and
emotions (n= 1 each). The epilepsy was classified as infantile
spasms in six patients, Lennox–Gastaut syndrome in four,
focal epilepsy in four others and unclassified in the others.
Status epilepticus was infrequent and mentioned in five
patients, including four females. Although seizure frequency
was variable, ranging from one per year to dozens per day,
most patients had multiple daily seizures (6/12 females and
12/16 males). Responses to antiepileptic treatments (AETs)
were variable, regardless of the treatment. The epilepsy was
responsive to AETs in 11/28 patients, pharmacoresistant in
15/28, and partially responded in 2/28. Seizures were more
frequently pharmacoresistant in males (n= 13/16) than in
females (n= 2/11; p= 0.002, Fisher’s exact test; Table 2,
Fig. 3c).
There was no correlation between the age at seizure onset
and the response to AETs. Likewise, there was no obvious
correlation between the age at seizure onset and the severity of
ID, because seizures started before 3 years in one of three
patients with mild or mild/moderate ID while seven patients
with severe to profound ID had a first seizure after the age of
3 years (Fig. 3d). Of note, two patients showed regression of
acquisitions, associated with seizure onset in one.
Clinical examination
Neurological examination data were available for 36
patients including 14/17 (1 female and 13 males) who had
not achieved independent walking. Hypotonia, global or
truncal, was the most frequently reported sign (n= 18; 11/
14 nonambulatory and 7/22 ambulatory patients), followed
by signs of corticospinal tract involvement (n= 8 in both
groups, with spasticity of limbs in 4/8), poor or absent eye
contact (n= 8 noticed in nonambulatory patients only),
clumsy/broad-based gait (n= 5, all ambulatory), and
dystonia (n= 2). Nine ambulatory patients had normal
neurological examinations.
Two of 34 patients had short stature. Occipitofrontal
circumferences (OFC) were available for 34 patients, with four
having microcephaly (OFC from −2.5 to −4 SD, including
three males), three having an OFC on −2 SD and all others
having an OFC ranging from −1.5 to +1.5 SD. Standard
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deviations of OFC were not significantly different between
males and females (p= 0.35, Wilcoxon–Mann–Whitney test).
Strabismus was mentioned in eight patients. Minor
dysmorphic features were reported in 23 patients, without
suggestions for a specific pattern in IQSEC2-related
encephalopathy.
Brain imaging (magnetic resonance image [MRI] n= 36,
computed tomography [CT] n= 2) was normal (21 patients)
or showed nonspecific abnormalities (18 patients), including
mild brain atrophy (n= 10), thin corpus callosum, and/or
abnormal signal of the cerebral white matter (mainly
periventricular T2 hyperintensities or myelination delay).
DISCUSSION
An increasing number of genes on chromosome X are
associated with human disorders manifesting in both sexes.
IQSEC2 is the prototype of X-linked genes where variants
were first identified in large families comprising almost
exclusively affected males. Recent evidence, however, indicates
that affected IQSEC2 female carriers could be nearly as
numerous as affected males.
The epilepsy phenotype associated with IQSEC2 variants
has been previously described from the study of 18 patients
recruited in epilepsy cohorts.25 We report on in this study 37
novel patients, including 7 without epilepsy. The develop-
mental outcome of patients with and without epilepsy was
similar. Furthermore, we observed no correlation between the
severity of ID, the age at seizure onset, and the response to
AETs. Thus, epilepsy appears to result from a parallel
pathophysiological process rather than being the underlying
cause of the neurodevelopmental disability.
IQSEC2 is a complicated gene expressing several isoforms
and it was tempting to speculate that the nature of pathogenic
changes present in males and females could be different.
However, our study shows that variant types and distribution
are globally similar in males and females, altering the same
longer isoform (NM_001111125.2/ NP_001104595.1) corre-
sponding to the synaptic IQSEC2/BRAG1 protein. Yet,
pathogenic variants found in females are mainly of truncating
type whereas affected males have both truncating and
missense variants, and the missense variants are most often
inherited from asymptomatic mothers. Strikingly, no males
with an entire IQSEC2 deletion have been reported so far,
suggesting that the absence of all isoforms could be lethal or
associated with a yet unrecognized disorder.
Genotype/phenotype correlation study in IQSEC2-related
encephalopathy should take into account the sex of patients
and variant type. Three recurrent truncating variants (p.
[Tyr269Thrfs*3], p.[Arg1055*], and p.[Arg1145*]) were
associated with severe neurodevelopmental disorder in both
males and females. However, the overall comparison of male
and female phenotypes revealed that females were globally
less affected than males. Although most females had severe
ID, only female patients had mild to moderate ID. Our study
showed that females can sit unsupported at a younger age,
have better language abilities, and a later onset of epilepsyTa
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Table 2 Summary and comparison of main developmental milestones and epilepsy data in males and females with IQSEC2
variants
Developmental milestones and epilepsy
Males Females All p value, test
Number of patients with IQSEC2 pathogenic variants 22 20 42
Mean/median age at the study in years 10.2/10.7 13/11 11.6 / 11.0
Motor milestones
Age at sitting unsupported in months: mean/median age
(number)
20.2/17.5 (n=
16)
10.2/9.75 (n=
12)
15.9 / 12.3 (n=
28)
p= 0.0015,
Wilcoxon–Mann–Whitney test
Age at walking unsupported in months: mean/median
age (number)
30.3/28.3 (n=
6)
24.5/23 (n=
15)
Unable to walk unsupported 16 1 17 p= 4.9E-5, Fisher's exact test
Language development (age >3 years)
Age at first words in years: mean/median age (number) NA (n= 2) 1.2/1.05 (n=
8)
Nonverbal patients 20/22 4/19 24 p= 6.2E-6, Fisher's exact test
Speaks several words 0 7 7
Associates words 2 3 5
Builds sentences 0 5 5
Use of hands (number)
Purposeful use of hands 10/21 14/17 24 p= 0.043, Fisher's exact test
Absent use of hands 7/21 1/17 8 p= 0.053, Fisher's exact test
Hand stereotypies 15/21 8/17 23 p= 0.18, Fisher's exact test
Severity of intellectual disability (number)
Mild 0 2 2
Mild–moderate 0 1 1
Moderate 0 3 3
Moderate–severe 0 3 3
Severe 12 8 20
Severe–profound 2 0 2
Profound 8 0 8
Behavior (number)
Behavioral disturbances 16 13 29
Autistic behaviors 12 8 20
Self-injurious behaviors 4 4 8
Epilepsy
Patients with epilepsy (number) 21 14 35 p= 0.04, Fisher's exact test
Seizure onset: mean median age (number) 23.9/23.5 (n=
20)
66.4/36 (n=
13)
40.6 / 34 (n=
33)
p= 0.1, Wilcoxon–Mann–Whitney
test
Seizure types (number)
Documented for: number 19 13 32
Atypical absences 11 6 17 p= 0.72, Fisher's exact test
Generalized tonic–clonic seizures 7 6 13 p= 0.72, Fisher's exact test
Tonic seizures 8 4 12 p= 0.71, Fisher's exact test
Atonic seizures 11 0 11 p= 0.0006, Fisher's exact test
Myoclonic seizures 9 1 10 p= 0.023, Fisher's exact test
Infantile spasms 8 1 9 p= 0.049, Fisher's exact test
Clonic 2 2 4
Dyscognitive 1 3 4
Resistance to AETs 13/16 2/11 p= 0.002, Fisher's exact test
AETs antiepileptic treatments
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with a better response to AETs. Furthermore, 21/22 (95%)
male patients had epilepsy versus 14/20 (70%) female patients,
and all males with truncating variants had epilepsy or EEG
abnormalities versus 13/18 females (72%). Considering the
equal number of truncating variants in both genders, these
data suggest that truncating IQSEC2 variants are generally
better tolerated in females than in males.
Our results also suggest that missense variants altering
functional IQSEC2 domains, and most particularly IQ and
SEC7, may be hypomorphic and better tolerated in females
(carrier mothers) due to a compensation by the normal allele
and can therefore be inherited over several generations
through healthy or mildly affected female carriers.11,18,37 Some
mutations in the SEC7 domain have previously been shown to
significantly decrease the ARFGEF activity of IQSEC2.
Interestingly, the role of BRAG1/IQSEC2 on AMPA receptors
is independent of its ARFGEF activity,19 suggesting that that
the pathophysiological mechanisms associated with missense
and truncating variants in males and females could be slightly
different. Splice-site variants also seem to be better tolerated in
females than in males, as exemplified by the splice-site variant
reported by Madrigal and collaborators.30 This is further
indicated by the occurrence of males with splice-site variants
inherited from unaffected mothers in our series.
In most X-linked disorders predominantly affecting males,
sparing of females is usually attributed to skewed XCI
favoring the expression of the normal allele.6 Study of XCI
patterns in females with IQSEC2 variants led to inconsistent
results, most affected females having a random inactivation
pattern while a few others show a tendency to XCI skewing.
Furthermore, no obvious correlation between the XCI status
and the severity of the phenotype seems to emerge. These
results should be interpreted by keeping in mind that IQSEC2
escapes XCI in humans.7 Contrary to some XCI escapee
genes, whose expression is increased in females, the expres-
sion of IQSEC2 is globally similar in males and females,
suggesting that regulatory mechanisms other than XCI are
able to compensate its dosage in females.7 Furthermore,
biallelic expression of many escapees including IQSEC2 is
inconstant depending on the tissue, and also possibly during
development.7 Altogether, our results suggest that pathogenic
variants lead to a loss-of-function of the longest isoform in
hemizygous males and haploinsufficiency of the same isoform
in heterozygous females.
Profound
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The phenotype of female IQSEC2 patients is close to that
associated with variants in SYNGAP1, also encoding an
important component of the excitatory postsynaptic density.38
Interestingly, the alterations of neuronal morphology and
accelerated maturation of dendritic spines observed in
neurons where IQSEC2 was knocked-down16 are reminiscent
of the premature development of dendritic spines observed at
synapses of Syngap1-deficient mice,39,40 suggesting that the
pathophysiological mechanisms causing SYNGAP1 and
IQSEC2 disorders are closely related to each other and both
lead to an abnormal development of glutamatergic synapses
during a critical developmental window. Maturation of
glutamatergic synapses is in particular regulated by a switch
in the composition of NMDA receptor (N2B subunit being
progressively replaced by N2A subunit) and accompanied by
a switch from BRAG1/IQSEC2 to BRAG2/IQSEC1 proteins.17
However, contrary to Syngap1-haploinsufficient mice in
which a premature accumulation of AMPA receptors was
observed, the number of AMPA receptors was decreased by
knockdown of IQSEC2.19 This opposite effect is in accordance
with differences existing between RasGap (SYNGAP1) and
ArfGef (IQSEC2) function.
In conclusion, our study provides evidence that IQSEC2
encephalopathy is related to the longest synaptic isoform and
that females are on average less affected than males,
suggesting that a correct dosage of IQSEC2 protein at the
synapse is crucial for normal brain development.
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